Specific Aims


The Coordinating Center will continue to work in concert with representatives of the NCI and with principal investigators holding federally-funded grants focused on SCLC (including U01 grants established as part of this Consortium, as well as R01 and other awards) to foster research on this particularly problematic cancer, with the ultimate goal of reducing the impact of this disease on society through better understanding of oncogenic mechanisms, disease pathologies, and therapeutic vulnerabilities. This understanding will refine and inform strategies of prevention, early detection, and clinical intervention.

The Specific Aims of this Coordinating Center, vis-à-vis members of the Consortium and the NCI, are as follows:

Specific Aim 1: Facilitation of data exchange and meetings among SCLC investigators

The Coordinating Center provides overall administrative oversight and coordination between the Consortium members and the NCI, and facilitates information sharing among the Consortium members through coordination of monthly teleconferences with a rotating agenda, and an annual investigators meeting.

Learn more about Specific Aim 1

Specific Aim 2: Centralized database support for preclinical and clinical SCLC resources

Complementing the biological resources in Aim 1, we are developing an integrated database for genetic, epigenetic, and gene expression data as well as treatment history and demographic data for human tissue samples and human tumor models. The Coordinating Center provides centralized biostatistical, bioinformatic, and –omic level data analysis support for the members of the Consortium.

Learn more about Specific Aim 2

Specific Aim 3: Characterization of and access to relevant preclinical models of SCLC

There has been a recent acceleration in generation of novel representative preclinical models of SCLC. Models of interest include cell lines for in vitro and in vivo work, innovative genetically engineered mouse models, and patient-derived models including from tumor (PDX) and from circulating tumor cells (CDX). We are cataloging the spectrum of relevant preclinical models to facilitate access to these resources within and beyond the U01 Consortium. We also incorporate human tumor tissue microarray resources as a platform for target validation.

Learn more about Specific Aim 3